Sentrx™ Animal Care, Inc. Announces Manufacturing Facility Expansion to Accommodate Accelerated Growth
1.7.2021 17:03:00 EEST | Business Wire | Press release
On May 20th, 2021 Sentrx Animal Care held a ribbon cutting ceremony to celebrate the completion and opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah. The expansion into this larger new facility represents a major milestone for the Salt Lake City based company. The design of the new space includes 1,689 square feet of ISO 7 clean room and 1,420 square feet of wet lab, accommodating the manufacturing capacity and capabilities required to support Sentrx’s accelerating growth in the United States, and in new markets abroad, as well as expanding R&D initiatives that build upon Sentrx’s patented BioHAnce platform technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005040/en/
Sentrx ribbon-cutting ceremony for new facility in Salt Lake City, Utah (Photo: Business Wire)
Working with Engage Contracting, Inc. as the general contractor on the project, Sentrx broke ground in November 2020. By the end of April 2021, manufacturing was online and fully validated in the new space. Sentrx also completed ISO audits in April and maintains ISO 13485 certification in this new facility.
“The completion of this project marks an exciting milestone for Sentrx,” said Brian Segebrecht, Chief Executive Officer. “Sentrx runs a vertically integrated manufacturing operation, procuring only raw materials and components from third parties. This allows for complete control over quality and the highly proprietary processes we have developed for manufacturing our three in-market formulations at large commercial scale. Our expansion to this new facility ensures our ability to remain a vertically integrated manufacturing operation with the capacity required to support the accelerating growth of our in-market products, as well as the robust pipeline of future innovation we have planned for the BioHAnce platform.”
Sentrx was founded on exclusive, worldwide rights to BioHAnce Technology, a patented and proprietary technology that uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that can be specifically modified for each formulation and particular tissue environment, including ocular and skin surfaces. It produces a cellular scaffolding with unique physical and chemical properties that enhances hydration, accelerates the body’s own healing processes, and extends duration in tissue. Sentrx currently sells three product formulations containing the BioHAnce Technology. In the US these products are marketed under the brand names Ocunovis™, Oculenis™ and Episanis™.
Related Information
Sentrx™ Animal Care, Inc. website: www.sentrxanimalcare.com
Online press releases: www.sentrxanimalcare.com/news
Sign up for the Sentrx veterinarian newsletter here
Product information:
Ocunovis™ BioHAnce™ Gel Eye Drops
Oculenis™ BioHAnce™ Ocular Repair Gel
Episanis™ BioHAnce™ Skin and Wound Gel
About Sentrx™ Animal Care, Inc.
Sentrx is a Salt Lake City-based animal health company that develops and manufactures veterinary wound care and ophthalmic products for companion animals. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals.
Sentrx was founded on technology from the University of Utah and collaborates with a variety of veterinary academic institutions and practicing veterinarians. The company’s unique combination of medicinal chemistry, bioengineering, and product manufacturing capabilities allow it to deliver cutting-edge animal care solutions. To learn more, visit our website at sentrxanimalcare.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005040/en/
Contact information
Mason Williams, Chief Commercial Officer
Sentrx™ Animal Care, Inc.
(801) 583-2050
mwilliams@sentrxanimalcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcement in July 2024, the RAINBOW study met its primary objective of demonstrating that nizubaglustat was safe and well tolerated. The study also showed encouraging signs of clinical efficacy, reducing disease progression and seizure burden in patients treated with nizubaglustat. “The publication of the RAINBOW data in a peer-reviewed journal represents an important milestone for Azafaros and for the broader lysosomal disease community,” said Stefano Portolano,
K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 04:00:00 EEST | Press release
South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from market entry to scale up in Korea - offered in a hybrid format - online or in person - with Demo Day held in Korea. The program runs Jul
Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More5.6.2026 00:46:00 EEST | Press release
The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the
Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 21:15:00 EEST | Press release
Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.com. Vycellix recently announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC)
Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 20:15:00 EEST | Press release
Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom